Literature DB >> 16642473

Frequent gene dosage alterations in stromal cells of epithelial ovarian carcinomas.

Hanna Tuhkanen1, Maarit Anttila, Veli-Matti Kosma, Seppo Heinonen, Matti Juhola, Seppo Helisalmi, Vesa Kataja, Arto Mannermaa.   

Abstract

Stromal cells are an active and integral part of epithelial neoplasms. We have previously observed allelic imbalance on chromosome 3p21 in both stromal and epithelial cells of ovarian tumors. This study was designed to explore gene dosage alterations throughout human chromosomes from stromal and epithelial cells of epithelial ovarian carcinomas. Thirteen stromal and 24 epithelial samples, microdissected from epithelial ovarian carcinomas, were analyzed using multiplex ligation-dependent probe amplification technique. Analysis covered 110 cancer related genes. Frequent genetic alterations were detected both in the stroma and epithelium of ovarian carcinomas. The mean number of altered genes per tumor was 10.8 in stroma and 23.6 in epithelium. In the stroma, the mean number of gains was 6.6 and of losses 4.2 and in the epithelium 13.7 and 9.9. The high number of changes associated with advanced tumor stage (p = 0.035) and death due to ovarian cancer (p = 0.032). The most frequent alteration was the deletion of the deleted in colorectal carcinoma (DCC) on chromosome 18q21.3 in 62% of samples. Loss of DCC was related to endometrioid subtype (p = 0.033). Large chromosomal aberrations were detected on the basis of alterations in adjacent genes. Most importantly, 38 genes showed similar genetic alterations (gain-gain or loss-loss) in stromal and epithelial compartments of 11 tumor pairs. Thus, frequent genetic alterations in stromal cells of epithelial ovarian carcinomas resembled those of malignant epithelial cells and may indicate a common precursor cell type. Epithelial-mesenchymal transition may generate transformed cancer cells and modify the tumor microenvironment with distinct properties.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16642473     DOI: 10.1002/ijc.21785

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  20 in total

Review 1.  Multiple myeloma mesenchymal stem cells: characterization, origin, and tumor-promoting effects.

Authors:  Michaela R Reagan; Irene M Ghobrial
Journal:  Clin Cancer Res       Date:  2011-11-07       Impact factor: 12.531

2.  In vitro models of pancreatic cancer for translational oncology research.

Authors:  Georg Feldmann; Sherri Rauenzahn; Anirban Maitra
Journal:  Expert Opin Drug Discov       Date:  2009-04-01       Impact factor: 6.098

Review 3.  Molecular biology of cancer-associated fibroblasts: can these cells be targeted in anti-cancer therapy?

Authors:  Tamas A Gonda; Andrea Varro; Timothy C Wang; Benjamin Tycko
Journal:  Semin Cell Dev Biol       Date:  2009-10-17       Impact factor: 7.727

Review 4.  MicroRNAs as mediators and communicators between cancer cells and the tumor microenvironment.

Authors:  F J Kohlhapp; A K Mitra; E Lengyel; M E Peter
Journal:  Oncogene       Date:  2015-04-13       Impact factor: 9.867

5.  Cancer-Associated Fibroblasts in Pancreatic Cancer Are Reprogrammed by Tumor-Induced Alterations in Genomic DNA Methylation.

Authors:  Qian Xiao; Donger Zhou; Agnieszka A Rucki; Jamila Williams; Jiaojiao Zhou; Guanglan Mo; Adrian Murphy; Kenji Fujiwara; Jennifer Kleponis; Bulent Salman; Christopher L Wolfgang; Robert A Anders; Shu Zheng; Elizabeth M Jaffee; Lei Zheng
Journal:  Cancer Res       Date:  2016-08-05       Impact factor: 12.701

6.  SDF-1α stiffens myeloma bone marrow mesenchymal stromal cells through the activation of RhoA-ROCK-Myosin II.

Authors:  Dong Soon Choi; Daniel J Stark; Robert M Raphael; Jianguo Wen; Jing Su; Xiaobo Zhou; Chung-Che Chang; Youli Zu
Journal:  Int J Cancer       Date:  2014-09-02       Impact factor: 7.396

Review 7.  Tumor stroma as targets for cancer therapy.

Authors:  Jing Zhang; Jinsong Liu
Journal:  Pharmacol Ther       Date:  2012-10-12       Impact factor: 12.310

8.  No evidence of clonal somatic genetic alterations in cancer-associated fibroblasts from human breast and ovarian carcinomas.

Authors:  Wen Qiu; Min Hu; Anita Sridhar; Ken Opeskin; Stephen Fox; Michail Shipitsin; Melanie Trivett; Ella R Thompson; Manasa Ramakrishna; Kylie L Gorringe; Kornelia Polyak; Izhak Haviv; Ian G Campbell
Journal:  Nat Genet       Date:  2008-04-13       Impact factor: 38.330

9.  MicroRNAs reprogram normal fibroblasts into cancer-associated fibroblasts in ovarian cancer.

Authors:  Anirban K Mitra; Marion Zillhardt; Youjia Hua; Payal Tiwari; Andrea E Murmann; Marcus E Peter; Ernst Lengyel
Journal:  Cancer Discov       Date:  2012-11-21       Impact factor: 39.397

10.  DNA hypermethylation, Her-2/neu overexpression and p53 mutations in ovarian carcinoma.

Authors:  Qinghua Feng; Georgios Deftereos; Stephen E Hawes; Joshua E Stern; Julia B Willner; Elizabeth M Swisher; Longfu Xi; Charles Drescher; Nicole Urban; Nancy Kiviat
Journal:  Gynecol Oncol       Date:  2008-08-30       Impact factor: 5.482

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.